morningstar.com·May 1, 2026
Amgen reported a 6% revenue growth and a 5% increase in non-GAAP earnings per share for the first quarter, while slightly raising its full-year revenue and EPS guidance. However, the company's shares dropped 5% in early trading following the announcement.
Amgen's first-quarter report shows a modest revenue and earnings growth, with management slightly increasing their full-year guidance. Despite this, Amgen's share price fell by 5% on May 1, suggesting potential market skepticism about the company's growth prospects or valuation at current levels. For an investor, this could indicate a buying opportunity if you believe in Amgen’s long-term fundamentals and future growth potential.